Announcements Trials
Browse Landscape

Status

Completed 19Recruiting 14Active not recruiting 11Terminated 6Withdrawn 4Not yet recruiting 3Unknown 2Enrolling by invitation 1Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 6Glioblastoma 4Recurrence 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Stomach Neoplasms 2Pheochromocytoma 2Ovarian Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Typical Teratoid Rhabdoid Tumor 1Thyroid Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Paraganglioma 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neuroectodermal Tumors, Primitive 1Meningioma 1Melanoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Glioma 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Neurofibroma, Plexiform × CNS × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡